Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression
Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells...
Main Authors: | Barbara Castella, Myriam Foglietta, Chiara Riganti, Massimo Massaia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01492/full |
Similar Items
-
Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
by: Barbara Castella, et al.
Published: (2018-11-01) -
Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma
by: Barbara Castella, et al.
Published: (2020-01-01) -
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status
by: Claudia Giannotta, et al.
Published: (2022-12-01) -
Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
by: Claudia Giannotta, et al.
Published: (2023-04-01) -
ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
by: Chiara Riganti, et al.
Published: (2018-06-01)